Industry, Regulators to Bolster Supply-Chain Standards

May 19, 2009
Manufacturers of generic and brand drugs can help protect the supply chain against economically motivated adulteration through industry consortiums such as Rx-360 and increased penalties for tampering, PhRMA says. The FDA held a public meeting to discuss how agency-regulated industries can recognize and prevent economically motivated adulteration such as contaminated heparin. PhRMA has recommended a few approaches, including measures that would be promoted by the consortium, Martin Van Trieste, chairman of the association’s quality technical group, said at the meeting.
Generic Line